Robert Yarchoan
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Yarchoan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05907759 · Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNational Cancer Institute (NCI) · recruiting · Lymphoma, Primary Effusion · principal investigator
- N/ANCT03300830 · Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman DiseaseNational Cancer Institute (NCI) · recruiting · Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma · principal investigator
- Ph1/Ph2NCT01495598 · Pomalidomide for Kaposi Sarcoma in People With or Without HIVNational Cancer Institute (NCI) · completed · Kaposi Sarcoma, Sarcoma, Kaposi · principal investigator
- Ph2NCT01441063 · Tocilizumab for KSHV-Associated Multicentric Castleman DiseaseNational Cancer Institute (NCI) · completed · Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia · principal investigator
- Ph2NCT01419561 · Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)National Cancer Institute (NCI) · recruiting · KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8 · principal investigator
- Ph2NCT00923936 · Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s SarcomaNational Cancer Institute (NCI) · completed · Sarcoma, Kaposi · principal investigator
- Ph1/Ph2NCT00019188 · Interleukin-12 in Treating Patients With AIDS-Related Kaposi's SarcomaNational Cancer Institute (NCI) · completed · Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma · study chair
- Ph1NCT00287495 · BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's SarcomaNational Cancer Institute (NCI) · terminated · Kaposi's Sarcoma, HHV-8, KSHV · principal investigator
- Ph2NCT00267865 · Chemotherapy and HAART to Treat AIDS-related Primary Brain LymphomaNational Cancer Institute (NCI) · completed · AIDS-Related-Primary Central Nervous System Lymphoma · principal investigator
- Ph2NCT00092222 · Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityNational Cancer Institute (NCI) · active not recruiting · Lymphoproliferative Disorder, HHV-8, Malignancy · principal investigator
- Ph2NCT00019240 · Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV InfectionNational Cancer Institute (NCI) · completed · Sarcoma · study chair
- Ph2NCT00019123 · Thalidomide in Treating Patients With HIV-Associated Kaposi's SarcomaNational Cancer Institute (NCI) · completed · Sarcoma · study chair
- Ph2NCT00055237 · Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative PatientsNational Cancer Institute (NCI) · completed · Kaposi's Sarcoma, HIV Infections, HIV Seronegativity · principal investigator
- N/ANCT00026793 · Assessment of Blood Vessel Density in Kaposi's Sarcoma LesionsNational Cancer Institute (NCI) · completed · Kaposi's Sarcoma · principal investigator
- N/ANCT00006518 · Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and CancerNational Cancer Institute (NCI) · recruiting · HIV, Kaposi's Sarcoma, Lymphomas · principal investigator
- N/ANCT00006171 · Effects of Potent Antiretroviral Therapy on Kaposi s SarcomaNational Cancer Institute (NCI) · completed · HIV Seropositivity, Kaposi's Sarcoma, HIV Infections · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Trials of Patients with AIDS-Related MalignanciesZIABC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $1,398,422 awarded in 2025Same name and institution; not confirmed by an ID
- Development of Preventive Strategies and Therapy for HIV InfectionZIASC006737 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2025 · $83,905 awarded in 2025Same name and institution; not confirmed by an ID
- Study of Tumor Pathogenesis and Development of Therapies for AIDS MalignanciesZIABC010885 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $1,314,516 awarded in 2025Same name and institution; not confirmed by an ID
- Study of and development of antiviral drugs against SARS-CoV2 proteaseZIABC011945 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2024 · $201,039 awarded in 2024Same name and institution; not confirmed by an ID
- Patient Oriented Research in Viral Malignancies and HIV-associated CancersZIABC011700 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2017 · $77,563 awarded in 2017Same name and institution; not confirmed by an ID
- Clinical trials of patients with AIDS-related malignanciesZ01BC010888 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $905,688 awarded in 2008Same name and institution; not confirmed by an ID
- Development of Novel Therapies for HIV InfectionZ01SC006737 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $618,518 awarded in 2008Same name and institution; not confirmed by an ID
- Pediatric HIVAIDS Clinical ResearchZ01SC010084 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $22,090 awarded in 2008Same name and institution; not confirmed by an ID
- Study of tumor pathogenesis and development of therapies for AIDS-malignanciesZ01BC010885 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $662,698 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:38 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- 785 citationsRCR 22.4
- 393 citationsRCR 11.8
- Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.Clin Pharmacol Ther · 1987376 citationsRCR 15.3
- Activity of thalidomide in AIDS-related Kaposi's sarcoma.J Clin Oncol · 2000239 citationsRCR 6.2
- CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.Ann Intern Med · 1991175 citationsRCR 5.4
- 152 citationsRCR 3.7
- Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.J Clin Pharmacol · 1986152 citationsRCR 4.9
- Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.Clin Pharmacol Ther · 1990142 citationsRCR 5.4
- 133 citationsRCR 4.1
- Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.J Clin Oncol · 1998132 citationsRCR 3.6